Comparison of the public health impact of RSV disease prevention options for infants: a static decision model of the us birth cohort [0.03%]
美国出生队列呼吸道合胞病毒（RSV）疾病预防选择的公共卫生影响比较：静态决策模型分析
Alexia Kieffer,Mehdi Ghemmouri,Samira Soudani et al.
Alexia Kieffer et al.
Background: In the U.S.A. three prophylactic interventions are approved for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in infants: nirsevimab and clesrovimab (extended half-...
Unravelling parental decision-making for adolescent HPV vaccination in China by COM-B framework: a discrete choice experiment [0.03%]
使用COM-B框架解开中国青少年HPV疫苗接种的父母决策机制：一种选择实验方法
Naiyang Shi,Shixin Xiu,Jiayu Wang et al.
Naiyang Shi et al.
Background: The paper provides a novel perspective beyond existing theoretical frameworks by integrating the COM-B model with discrete choice experiments (DCEs) to quantify parental decision-making dynamics for adolescent...
Cost-effectiveness of maternal vaccination against respiratory syncytial virus in Hong Kong: a decision-analytical analysis [0.03%]
香港通过决策分析评估母体接种呼吸道合胞病毒疫苗的成本效益研究
Yingcheng Wang,Mingjun Rui,Qiran Wei et al.
Yingcheng Wang et al.
Background: Maternal vaccination against respiratory syncytial virus (RSV) showed high vaccine efficacy in preventing severe RSV-associated events in newborns in randomized controlled trials. This cost-effectiveness study...
Understanding the role of COVID-19 vaccination in all-cause healthcare resource utilisation among adults with long covid in the Uk primary care setting: data from the 2022-2023 respiratory virus season [0.03%]
了解COVID-19疫苗在英国初级保健环境中长期感染成年人口中的全因医疗卫生资源利用中的作用：来自2022-2023年呼吸道病毒季节的数据
Kiran K Rai,Hannah Gowman,Cale S Harrison et al.
Kiran K Rai et al.
Background: The role COVID-19 vaccination on healthcare resource utilization (HCRU) and cost remains unclear, especially during Omicron predominance and among high risk UK populations. ...
An analysis of causality assessed serious and severe adverse events following COVID-19 vaccines administered from January 2021 to September 2022 in India [0.03%]
2021年1月至2022年9月印度新冠疫苗接种后严重和严重的因果评估不良事件分析
Awnish Kumar Singh,Neneh Feren,Rekha Thapar et al.
Awnish Kumar Singh et al.
Background: Vaccine safety surveillance is one of the important elements of immunization program. Causality assessment of adverse events and dissemination of their results are equally important to ensure quality of vaccin...
Safety of live attenuated vaccines in immunocompromised individuals and pregnant women: a systematic literature review [0.03%]
减毒活疫苗在免疫缺陷人群和孕妇中的安全性系统文献回顾
Giorgia Tiozzo,Adrianne de Roo,Hinko S Hofstra et al.
Giorgia Tiozzo et al.
Background: Live-attenuated vaccines (LAVs) are typically contraindicated for immunocompromised patients and pregnant women, although the potential benefits of vaccination with LAV in these populations should not be overl...
Safety profile and medium- to long-term protection of the Recombinant Zoster vaccine (RZV) in a cohort of high-risk patients: real-world data from a General Hospital in Southern Italy, 2021-2025 [0.03%]
重组带状疱疹疫苗(RZV)在高危患者人群中的安全性和中至长期保护效果：2021-2025年意大利南部一家综合医院的真实世界数据
Pasquale Stefanizzi,Lorenza Moscara,Claudia Palmieri et al.
Pasquale Stefanizzi et al.
Introduction: Recombinant Zoster Vaccine (RZV) is recommended for Herpes Zoster (HZ) prevention in high-risk patients over 18 years of age. Research desig...
Off-Label use of vaccines may save lives and money: lessons from the province of Quebec, Canada [0.03%]
越界使用疫苗可能节约生命和金钱——来自加拿大魁北克省的启示
Philippe De Wals,Caroline Quach
Philippe De Wals
Introduction: In Canada, vaccines are authorized by Health Canada but publicly funded programs are of provincial/territorial jurisdiction. Off-label (OL) use of vaccines has been frequently implemented in Quebec over the ...
Healthcare providers' preferences for pediatric pneumococcal vaccination recommendations in the United States [0.03%]
美国儿科肺炎球菌疫苗接种指南的医疗提供者偏好
Jeffrey Vietri,Kelley Myers,Liping Huang et al.
Jeffrey Vietri et al.
Background: A 20-valent pneumococcal conjugate vaccine (PCV20) was recently licensed for use in children by the United States Food and Drug Administration. The objective of this study was to assess healthcare providers' (...
Correction [0.03%]
改正
Published Erratum
Expert review of vaccines. 2025 Dec;24(1):991. DOI:10.1080/14760584.2025.2588050 2025